Biotech | January 22, 2022
Pfizer and OPKO update on the Biologics License Application for Somatrogon
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The upgrade centres on new machinery and advanced technology designed to expand capacity and sharpen turnaround times in increasingly competitive flexible packaging markets.
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
